| Literature DB >> 33311002 |
Masaji Mase1,2, Kanae Hiramatsu3, Noriko Nishijima4, Hiroshi Iseki1, Satoko Watanabe1.
Abstract
We have developed a polymerase chain reaction (PCR) assay to facilitate detection of the major disease-associated serotypes of fowl adenovirus (FAdV) including serotypes 1, 2, 4, 8a and 8b; primers were designed based on serotype-specific sequences of the hexon gene. We tested field isolates from chickens diagnosed with inclusion body hepatitis, gizzard erosion and hydropericardium syndrome together with reference FAdV strains characterized in Japan. We found that the primers were serotype specific; appropriate amplification of serotype-specific hexon genes was confirmed by sequence analysis of the PCR products. This PCR assay will be useful for detection of FAdV and for differentiation between disease-associated serotypes.Entities:
Keywords: detection; fowl adenovirus; polymerase chain reaction; serotype-specific
Mesh:
Year: 2020 PMID: 33311002 PMCID: PMC7870399 DOI: 10.1292/jvms.20-0400
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Fowl adenoviruses isolated from diseased chickens used in this study
| Virus | Clinical diagnosis | The results of typing by PCR | Reference | |||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 4 | 8a | 8b | ||||
| Strains identifid in previous studies* | ||||||||
| JP/Kagawa/2000GE (1) | Gizzard Erosion | + | - | - | - | - | Mase | |
| S-PL1 (2) | Inclusion body hepatitis | - | + | - | - | - | Mase | |
| JP/Gunma/2009IBH (2) | Inclusion body hepatitis | - | + | - | - | - | Mase | |
| JP/Tokushima/2010IBH (2) | Inclusion body hepatitis | - | + | - | - | - | Mase | |
| JP/Saga/97 (8a) | Inclusion body hepatitis | - | - | - | + | - | Mase | |
| JP/LVP-1/96 (4) | Hydropericardium syndrome | - | - | + | - | - | Mase | |
| H-1 (4) | Hydropericardium syndrome | - | - | + | - | - | Mase | |
| PARC-97 (4) | Hydropericardium syndrome | - | - | + | - | - | Mase | |
| PARC-98 (4) | Hydropericardium syndrome | - | - | + | - | - | Mase | |
| JP/Oita/2018IBH (8b) | Inclusion body hepatitis | - | - | - | - | + | Mase | |
| JP/Tokushima/2019IBH (8b) | Inclusion body hepatitis | - | - | - | - | + | Mase | |
| Field isolates in this study | ||||||||
| JP/Mie/2009IBH | Inclusion body hepatitis | - | - | + | - | - | This study | |
| JP/Kagoshima/2010IBH | Inclusion body hepatitis | - | + | - | - | - | This study | |
| Mixed infected cases for this study | ||||||||
| JP/Sga/98 | Inclusion body hepatitis | - | + | - | + | - | This study | |
*Serotypes shown in parenenses.
PCR primers used in this study
| Type | Direction | Sequence (5′-3′) | Genomic position | Length (bp) |
|---|---|---|---|---|
| 1 | Forward | ATTTTCAACACCTGGGTGGAGAGCA | 18691–19518 (in CELO, GenBank Acc. No.U46933) | 828 |
| Reverse | CACGTTGCCCTTATCTTGC | |||
| 2 | Forward | CCCAATATGATTCTACAGTCCA | 21670–22388 (in SR-48, GenBank Acc. No.KT862806) | 719 |
| Reverse | GAGATGGGTATTGTGGGTTCGTATTCGG | |||
| 4 | Forward | CCAACGCCACTACCAACT | 21567–21856 (in KR-5, GenBank Acc. No.HE608152) | 290 |
| Reverse | CCAGTTTCTGTGGTGGTTG | |||
| 8a | Forward | TAACCCCTATGAGAATACCACT | 20682–21063 (in TR-59, GenBank Acc. No.KT862810) | 382 |
| Reverse | ATTGACCGTTCCGTACTCGAT | |||
| 8b | Forward | AAGAACGAGGCGCAAAACACAGCTA | 20631–20891 (in 764, GenBank Acc. No.KT862811) | 261 |
| Reverse | GTCTAACACGTAGTAAGGCGTTGTTCCA | |||
| All | Forward | GAYRGYHGGRTNBTGGAYATGGG | 18571–19361 (in CELO, GenBank Acc. No.U46933) | ~900 [ |
| Reverse | TACTTATCNACRGCYTGRTTCCA |
Fig. 1.Agarose gel electrophoresis of amplification products from the reference fowl adenovirus strains using type-specific primers. Panels A, B, C, D and E include the results of primer-specific PCR-amplification applied to types 1, 2, 4, 8a and 8b, respectively. Lane M, 100bp molecular weight marker DNA ladder; lane 1, Ote; lane 2, SR-48; lane 3, SR-49; lane 4, KR-5; lane 5, TR-22; lane 6, CR-119; lane 7, YR-36; lane 8, TR-59; lane 9, TR630.
Fig. 2.Agarose gel electrophoresis of amplification products from field fowl adenovirus (FAdV) strains using serotype-specific primers. Field isolates include (A) JP/Kagawa/2000GE, (B) JP/Tokushima/2010IBH, (C) JP/LVP-1/96 (D) JP/Saga/97, (E) JP/Oita/2018IBH and (F) JP/Saga/98. Lane M, 100 bp molecular weight marker DNA ladder; lane 1, primers for type 1; lane 2, primers for type 2; lane 3, primers for type 4; lane 4, primers for type 8a, lane 5, primers for type 8b; lane 6, consensus primers for FAdV.